Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07233239 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
A Phase 1 study of Focal Seizures, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT07233239: Recruiting Phase 1 study of Focal Seizures, sponsored by Jazz Pharmaceuticals.
NCT07233239 is a Phase 1 study of Focal Seizures that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 100 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07233239, a Phase 1 study of Focal Seizures, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).
Conditions Studied
Interventions
- DRUG CBD-OS
Study Locations (20)
Georgia
- Emory University - Atlanta
- Savannah Neurology Specialists - Savannah
Michigan
- Wayne State University - Detroit
- Corewell Health - Grand Rapids
New Jersey
- Hackensack Meridian Neuroscience Institute at JFK University Medical Center - Edison
- Saint Peter's University Hospital - New Brunswick
North Carolina
- Onsite Clinical Solutions - Charlotte
- Velocity Clinical Research at Raleigh Neurology - Raleigh
Ohio
- Cincinnati Children's Hospital - Cincinnati
- University of Cincinnati, Gardner Neuroscience Institute - Cincinnati
Arizona
- Banner University Medical Center-Phoenix - Phoenix
California
- UC San Diego - La Jolla
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-26 |
| Est. Completion | 2027-11-29 |
| Phase | Phase 1 |
What NCT07233239 shows while recruiting
NCT07233239 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Focal Seizures appearing as the primary indexed condition, and to 1 intervention - of which CBD-OS is the first listed.
NCT07233239 names 20 study sites across 15 states, led by Georgia, Michigan, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07233239 about?
NCT07233239 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures". Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participant...
What is the current status of trial NCT07233239?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-11-26. Estimated completion is 2027-11-29.
What conditions does trial NCT07233239 study?
This clinical trial studies the following conditions: Focal Seizures.
What interventions are being tested in trial NCT07233239?
The interventions under investigation include: CBD-OS (DRUG).
Who is sponsoring clinical trial NCT07233239?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07233239 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07233239's enrollment target sits among peer trials
100 547th of 2000 higher than 1,411 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI